Cancer Prevention Research CR Magazine Sign up for eTOC's!
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Prevention Research 2, 557, June 1, 2009. Published Online First May 26, 2009;
doi: 10.1158/1940-6207.CAPR-08-0188
© 2009 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
1940-6207.CAPR-08-0188v1
2/6/557    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mavropoulos, J. C.
Right arrow Articles by Freedland, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mavropoulos, J. C.
Right arrow Articles by Freedland, S. J.
Related Collections
Right arrow Preclinical Intervention
Right arrow Preclinical Intervention: In Vivo (Animals): Drugs, Nutritional Interventions, Mechanisms

Research Articles

The Effects of Varying Dietary Carbohydrate and Fat Content on Survival in a Murine LNCaP Prostate Cancer Xenograft Model

John C. Mavropoulos1, W. Cooper Buschemeyer, III2, Alok K. Tewari3, Dmitriy Rokhfeld2, Michael Pollak8, Yunhua Zhao8, Phillip G. Febbo3,4,5, Pinchas Cohen9, David Hwang9, Gayathri Devi6, Wendy Demark-Wahnefried10, Eric C. Westman4, Bercedis L. Peterson5, Salvatore V. Pizzo1,5 and Stephen J. Freedland1,2,5,7

Authors' Affiliations: 1 Department of Pathology, 2 Division of Urology and Duke Prostate Center, Department of Surgery, 3 Center for Genomic Medicine, Institute for Genome Sciences and Policy, 4 Department of Medicine, 5 Duke Comprehensive Cancer Center, 6 Division of Experimental Surgery, Department of Surgery, and 7 Department of Surgery, Durham VA Medical Center, Duke University Medical Center, Durham, North Carolina; 8 Department of Oncology, Lady Davis Research Institute, McGill University, Montreal, Canada; 9 Department of Pediatrics, University of California at Los Angeles School of Medicine, Los Angeles, California; and 10 Department of Behavioral Science, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Stephen Freedland, Box 2626, Duke University Medical Center, Durham, NC 27710. Phone: 919-668-8361; Fax: 919-668-7093; E-mail: steve.freedland{at}duke.edu.


Purpose: Numerous dietary factors elevate serum levels of insulin and insulin-like growth factor I (IGF-I), both potent prostate cancer mitogens. We tested whether varying dietary carbohydrate and fat, without energy restriction relative to comparison diets, would slow tumor growth and reduce serum insulin, IGF-I, and other molecular mediators of prostate cancer in a xenograft model.

Experimental Design: Individually caged male severe combined immunodeficient mice (n = 130) were randomly assigned to one of three diets (described as percent total calories): very high-fat/no-carbohydrate ketogenic diet (NCKD: 83% fat, 0% carbohydrate, 17% protein), low-fat/high-carbohydrate diet (LFD: 12% fat, 71% carbohydrate, 17% protein), or high-fat/moderate-carbohydrate diet (MCD: 40% fat, 43% carbohydrate, 17% protein). Mice were fed to maintain similar average body weights among groups. Following a preliminary feeding period, mice were injected with 1 x 106 LNCaP cells (day 0) and sacrificed when tumors were ≥1,000 mm3.

Results: Two days before tumor injection, median NCKD body weight was 2.4 g (10%) and 2.1 g (8%) greater than the LFD and MCD groups, respectively (P < 0.0001). Diet was significantly associated with overall survival (log-rank P = 0.004). Relative to MCD, survival was significantly prolonged for the LFD (hazard ratio, 0.49; 95% confidence interval, 0.29-0.79; P = 0.004) and NCKD groups (hazard ratio, 0.59; 95% confidence interval, 0.37-0.93; P = 0.02). Median serum insulin, IGF-I, IGF-I/IGF binding protein-1 ratio, and IGF-I/IGF binding protein-3 ratio were significantly reduced in NCKD relative to MCD mice. Phospho-AKT/total AKT ratio and pathways associated with antiapoptosis, inflammation, insulin resistance, and obesity were also significantly reduced in NCKD relative to MCD tumors.

Conclusions: These results support further preclinical exploration of carbohydrate restriction in prostate cancer and possibly warrant pilot or feasibility testing in humans.

Key Words: prostate cancer • diet • carbohydrate • fat • ketogenic • insulin • IGF-I • AKT




This article has been cited by other articles:


Home page
Clin. Chem.Home page
S. J. Freedland, C. D. Williams, and E. M. Masko
Adiponectin and Prostate Cancer Mortality: To Be or Not to Be Skinny?
Clin. Chem., January 1, 2010; 56(1): 1 - 3.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2009 by the American Association for Cancer Research.